“Our goal is to support patients throughout their entire journey with an intelligence chat system that not only evaluates them, but also answers many questions when their treating physician is not available, which is very common,” says Juan Fulla, MD, MSc.
In this interview, Juan Fulla, MD, MSc, discusses an artificial intelligence (AI)-based chat system that can assist in the follow-up of patients with urologic conditions. Fulla is the chief of the robotic program and an associate professor of urology at the University of Chile in Santiago, Chile.
Video Transcript:
I would like to mention an innovative project I'm working on. It's called UroAssist; it's a platform that will integrate various urological conditions. Currently, it focuses only on kidney stones and also BPH. Our goal is to support patients throughout their entire journey with an intelligence chat system that not only evaluates them, but also answers many questions when their treating physician is not available, which is very common. This is very relevant, for example, in the post-operative follow-up, where many patients are unable to retain all the information given at a discharge. And often, they have numerous questions that could be easily addressed. This, we think, allows physicians to save time and of course, focus on more critical tasks. UroAssist serves as a follow-up tool, basically, by asking patients questions through questionnaires to monitor their progress very objectively, but also providing physicians with clear evidence of the patient's evolution over the time.
This transcription has been edited for clarity.
Destigmatizing Urology: Dr. Winter discusses STDs/STIs
March 22nd 2022“We need to just approach STIs as the medical conditions they are because until we do, and until we take those stigmas away, people will truly have resistance to discussing it, hesitance to discussing it, and resistance to diagnosis and intervention,” says Ashley Winter, MD.
Predictive model quantifies risk of antibiotic resistance in uUTI
May 24th 2024The predictive models identified the number of previous UTI episodes, prior β-lactam nonsusceptibility, prior fluoroquinolone treatment, Census Bureau region (particularly in the South), and race as key predictors of having a non-susceptible isolate to 3 or more antibiotic classes.